CeriBell, Inc.
NASDAQ:CBLLMedical - Devices
+$0.25 today
- Market cap
- $995.34M
- Beta
- 0.84
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$1.60
Volume 0.41M
Average 0.29M
CBLL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
CeriBell, Inc.NASDAQ: CBLL
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $3.72M rose 58.6% year over year, behind the +94.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 10.8% from the prior quarter. Over 3 fiscal years it compounded at +15.5% a year.
Context
- Stock-based compensation amounted to 13.7% of revenue in FY2025, up 5.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +58.6% toward the trailing-twelve-month pace of +94.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.22M USD
- Year-over-year change
- +125.9%
- 3-year CAGR
- +15.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.22M | +125.9% |
| FY2024 | 2024-12-31 | 5.41M | +102.1% |
| FY2023 | 2023-12-31 | 2.68M | -66.2% |
| FY2022 | 2022-12-31 | 7.93M | — |
Stock-Based Compensation vs competitors
How CBLL compares with its peers on the latest reported figures
- CBLL's LTM Mar 2026 stock-based compensation of $13.6M is the 2nd largest of the 7 companies compared; the peer median is $8.07M.
- Its year-over-year change of +94.2% is the highest of 7, against a peer median of +7.3%.
- Stock-based compensation amounts to 14.3% of revenue for CBLL, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $49.04M | +44.9% | -6.8% | 3.3% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $13.6M | +94.2% | +15.5% | 14.3% |
| LTM Mar 2026 | $11.51M | +11.1% | +41.7% | 19.5% | |
| LTM Mar 2026 | $10.74M | +3.6% | +9.9% | 10.8% | |
| LTM Mar 2026 | $5.4M | -5.3% | -7.8% | 3.6% | |
| LTM Mar 2026 | $2.43M | +26.0% | -10.4% | 7.0% | |
| LTM Mar 2026 | $1.21M | -17.0% | -6.7% | 2.2% | |
| Peer median (excluding CBLL) | $8.07M | +7.3% | -6.8% | 5.3% | |
Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (37.16M) | (29.46M) | (40.46M) | (53.41M) |
| Depreciation & Amortization | 497K | 847K | 1.14M | (670K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.93M | 2.68M | 5.41M | 12.22M |
| Change in Working Capital | (3.88M) | (3.7M) | (3.17M) | 633K |
| Accounts Receivables | (3.96M) | (3.43M) | (3.51M) | (4.18M) |
| Inventory | (1.9M) | (1.79M) | (1.07M) | (351K) |
| Accounts Payables | 124K | 309K | 250K | 1.75M |
| Other Working Capital | 1.85M | 1.22M | 1.16M | 3.41M |
| Other Non-Cash Items | 621K | 477K | 2.03M | 418K |
| Operating Cash Flow | (32M) | (29.16M) | (35.04M) | (40.81M) |
| Capital Expenditures | (516K) | (983K) | (1.34M) | (767K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (210.82M) |
| Sales of Investments | 0 | 0 | 0 | 94.2M |
| Other Investing Activities | (883K) | (780K) | (258K) | (755K) |
| Investing Cash Flow | (1.4M) | (1.76M) | (1.6M) | (118.14M) |
| Debt Repayment | (39K) | (3.75M) | 7.91M | 0 |
| Common Stock Issued | 0 | 0 | 188.92M | 5.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 154K | 932K | (304K) | (386K) |
| Financing Cash Flow | 49.81M | (2.82M) | 196.52M | 5.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.4M | (33.74M) | 159.88M | (153.89M) |
| Free Cash Flow | (32.52M) | (30.14M) | (36.38M) | (41.58M) |
CeriBell, Inc.
NASDAQ:CBLL
Intrinsic Alpha fair value
Locked
Current Price
$25.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.